Skip to main content
. 2012 Apr 18;2012(4):CD003869. doi: 10.1002/14651858.CD003869.pub3

Murray 1997

Methods RCT: enrolled:445 evaluated: 429
Participants Inclusion: 1. Proof of underlying primary 2. Measureable brain lesion(s) on CT/MRI 3. KPS ≥ 70 4. NFC 1 or 2 Exclusion: 1. Primary site hematopoeitc origin 2. Metastatic lymphoma involving meninges
Interventions 5440 cGy/34 fr (BID over 17 days) versus 3000 cGy/10 fr (over 10 days)
Outcomes 1. Survival (2. Acute toxicity)
Notes QS = 2